Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

10 stocks we like ... for the development of new drugs. At the time, GSK made a $300 million equity investment in 23andMe, which is more than the amount Regeneron could end up paying for the ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Regeneron Pharmaceuticals ... building the world's greatest ...

This typically results in pricing pressure and a gradual loss of market share for branded drugs. Regeneron's Eylea HD ... In an early-stage trial, 10 of 11 children showed improvements in hearing ...

There is no pause button to stop the world from spinning ... a version of the SARS-CoV-2 virus that circulated then. Regeneron Pharmaceutical reached an agreement to buy the consumer genetics ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

His innovation reduces the cost per gram from $75.00 to just $12.00, and the production time per batch from 9 days to just 5.